Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch of Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg.
Glenmark's Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg is the authorized generic to Savella®2 Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg.
According to IQVIA sales data for the 12-month period ending January 2026, the Savella® Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg market2 achieved annual sales of approximately $102.9 million.